MDT-AP-2869
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 18.96
- os_event
- false
- age_years
- 11
- sex
- M
- new_clusters
- C4
- umap1_2d
- 3.951752678
- umap2_2d
- 4.380811247
- umap1_3d
- 1.075749385
- umap2_3d
- -1.040993731
- umap3_3d
- -2.6466399
- dataset
- Med-Taylor
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1RXZ3BP7 | low-grade glioma | — | 0.950 |
| 2 | BS_YY5B2XDD | pilocytic astrocytoma | — | 0.947 |
| 3 | MDT-AP-2936 | Med | Medulloblastoma | 0.943 |
| 4 | BS_W97QQYKQ | Ganglioglioma | — | 0.938 |
| 5 | MDT-AP-3331 | Med | Medulloblastoma | 0.935 |
| 6 | s0122206 | — | — | 0.934 |
| 7 | MDT-AP-3277 | Med | Medulloblastoma | 0.933 |
| 8 | TCGA-77-8131-01A-11R-2247-07 | — | cohortSQ1 | 0.932 |
| 9 | MDT-AP-0363 | Med | Medulloblastoma | 0.932 |
| 10 | BS_S9929Z8B | Ganglioglioma | — | 0.932 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.520 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |